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Mycobacterium tuberculosis isolates cultured from 6
patients associated with an isoniazid-resistant M. tubercu-
losis outbreak acquired rifampicin resistance. The rpoB
gene sequence showed that resistance was associated
with rare mutations in each isolate. Three isolates had a
mutation outside the rifampicin resistance–determining
region.
I
n January 2000, 4 cases of smear-positive pulmonary
tuberculosis (TB) caused by Mycobacterium tuberculosis
in young men from the local community were identified
during a 1-week period at a hospital in north London,
United Kingdom (1). Three isolates were shown to be iso-
niazid-monoresistant TB. Further investigation showed 155
confirmed or probable cases, 132 in London and 23 outside
London, which suggests a large outbreak of a unique strain
in the London area (2). Confirmed case-patients were
defined as patients with isolates of M. tuberculosis resistant
to isoniazid that had the same band pattern on restriction
length polymorphism typing (RFLP); these patients were
residents of London at the time of their diagnosis, which
had been made since January 1995 (2). Probable cases were
defined as for confirmed cases except that isolates under-
went rapid epidemiologic typing [RAPET] but are awaiting
RFLP typing (2). RAPET is a rapid screening molecular
typing method developed at the Mycobacterium Reference
Unit (MRU) (3). In October 2002, the TB isolate from 1
patient associated with the outbreak had developed resist-
ance to rifampicin. Initially, the isolate was tested with a
commercial line probe rifampicin resistance–determining
hybridization assay, Inno-LiPA (Innogenetics Belgium,
Gent, Belgium). However, the line probe assay failed to
identify rifampicin resistance in this isolate, and rifampicin
resistance was only detected on phenotypic antimicrobial
sensitivity testing at MRU. Subsequently, 5 additional
rifampicin-resistant isolates from different patients
associated with this outbreak were identified at MRU. The
aim of this study was to determine the basis for the
rifampicin resistance in these 6 isolates by sequencing the
entire rpoB gene. 
Rifampicin resistance can occur as a result of mutations
on the rpoB gene that encodes the β-subunit of RNApoly-
merase (4). More than 95% of these mutations occur on an
81-bp fragment of the gene between bases 1276 and 1356
(432–458 in the rpoB gene of M. tuberculosis and codon
507–534 in the Escherichia coli rpoB gene) (5,6). This
region is known as the rifampicin resistance–determining
region (RRDR), or “hotspot,” and is used as a target for
direct sequencing and commercial line probe assays.
The Study
The isoniazid-monoresistant and multidrug-resistant
tuberculosis (MDR-TB) isolates were obtained from the
patients’source hospital or MRU. All isolates were identi-
fied as belonging to the same strain of M. tuberculosis
(RAPET or IS6110  typing), and all drug-susceptibility
testing was carried out at MRU according to standard pro-
cedures. The wildtype control isolate used for these stud-
ies was M. tuberculosis, H37Rv (ATCC, 9360 National
Collection of Type Culture, London, UK). Three isolates,
018, 483, and 915, were from patients in whom MDR-TB
developed as a result of poor compliance with therapy,
whereas isolates 604, T7, and 371 were from patients who
contracted primary MDR-TB.
DNAwas prepared from the 6 isolates of M. tuberculo-
sis by emulsifying 2–3 colonies in 400 µL Tris-EDTA
buffer and heating the suspension in a water bath for 40
min at 80°C. Polymerase chain reaction (PCR) was per-
formed on the extracted DNA with 6 sets of primers
designed to amplify 6 overlapping fragments of the rpoB
gene from the 6 M. tuberculosis isolates (Table). Ten
microliters of DNA was added to the PCR mix containing
81.4  µL PCR-quality water, 10 µL potassium chloride
buffer (Bioline Ltd., London, UK), 0.4 µL of each primer
(100 mmol) (Sigma-Genosys Ltd., Haverhill, UK), 3 µL
deoxynucleoside triphosphates (5 mmol), and 1 µLT a q
(Bioline). The amplification was performed on a Techgene
thermal cycler (Techne, Princeton, NJ, USA). PCR prod-
ucts were separated by gel electrophoresis on a 1.5%
agarose gel, and DNA bands were stained with ethidium
bromide. Primers and excess nucleotides were removed
from the amplified DNAwith a PCR clean-up kit (Qiagen,
Inc., Valencia, CA, USA). The amount of DNA in the
cleaned-up product was quantified by comparing the inten-
sity of the band to bands of known intensity in a
HyperLadder marker (Bioline).
Forward and reverse cycle sequencing reactions were
performed with the Big Dye Terminator Cycle
Sequencing Ready Reaction DNA sequencing kit
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Briefly, 40 ng of cleaned-up DNA was added to 10.8 µL
PCR-quality water, 3 µL buffer, 3.2 µL of forward or
reverse 1 mmol primer, and 1 µL of cycle sequencing
ready reaction mix. The labeled DNA was precipitated by
adding 14.5 µL PCR-quality water, 62.5 µL 95% ethanol,
and 3 µL sodium acetate solution (2.3 mol/L) and cen-
trifuging (13,000 × g, 15 min, 4°C). The supernatant was
removed with a fine-tipped pipette, and the pellet was
cleaned with 200 µL 70% ethanol and then recentrifuged
(13,000  × g, 15 min, 4°C). Again the supernatant was
removed, and the pellet was dried at 37°C for 30 min.
Four microliters of formamide and 1 µL of dextran load-
ing buffer were added to each pellet, and 1.5 µL of sam-
ple was added to each well of the sequencing gel. The 6
fragments of the rpoB gene from each of the 6 isolates
were then sequenced with an ABI 377 Applied
Biosystems sequencer. The sequences obtained from each
isolate were joined together to form a continuous whole
gene sequence, aligned with ClustalW (http://www.ebi.ac.
uk/clustalw/) and compared to the wildtype to identify
base-pair mismatches.
In addition, all 6 isolates were tested with a line probe
resistance–determining hybridization assay, Inno-LiPA
(Innogenetics Belgium), as described in the manufactur-
er’s instructions. Briefly, an 81-bp region of the rpoB gene
was amplified with biotinylated primers, which yielded a
biotinylated target sequence, and hybridized with specific
oligonucleotide probes immobilized on a parallel strip.
After hybridization, streptavidin labeled with alkaline
phosphatase was used to detect any hybrids. Inno-LiPA
consists of 10 oligonucleotide probes (19–23 bases in
length), encompassing the 81-bp region (RRDR) of the
rpoB gene. One is specific for M. tuberculosis complex,
whereas the other 5 partially overlapping wildtype probes
(S1–S5) cover the region from positions 507 to 534 of the
rpoB gene. These S-probes hybridize to the wildtype
(rifampicin-sensitive) DNA sequence. Failure of any of
these S-probes to hybridize indicates that a mutation has
occurred. Four other probes (R2, R4a, R4b, and R5) are
specific for amplicons carrying the most common rpoB
mutation that confers rifampicin resistance. 
The results of the Inno-LiPA assay showed 5 of the 6
isolates, which were phenotypically rifampicin-resistant,
were negative. The target DNAhybridized to all 5 wildtype
S-probes and none of the R-probes, which demonstrated
that the assay failed to detect rifampicin resistance in these
5 isolates. The Inno-LiPA assay cannot detect mutations
outside the RRDR. Failure to detect rare mutations within
the RRDR may be caused by nonspecific hybridization of
the wildtype S-probes because of slight fluctuations in tem-
perature during the hybridization process. Isolate 483
showed a weak DNA hybridization reaction with the S4
probe, indicating that a mutation was present on codon 451
(codon 526 in Escherichia coli). The exact nature of the
mutation could not be determined with this assay.
Analysis of the sequence data identified specific muta-
tions in rpoB in all 6 strains studied (Figure 1). Three had
mutations within the RRDR, and of these, 2 were C-to-G
mutations at codon 456, inducing a serine to tryptophan
amino acid conversion (S456W). The third was an A-to-G
mutation at codon 451, resulting in a change from histidine
to arginine (H451R) (Figure 1). No other mutations were
identified in the DNA sequences outside the RRDR in
these 3 isolates. The 3 other isolates had the mutation G to
T at codon 176, outside the RRDR, which caused a change
from valine to phenylalanine (V176F). Neither RRDR
mutations nor any other mutations were found in the rpoB
gene sequences of these 3 isolates. 
Of the mutations found within the RRDR, H526R
occurs in <4%, and S531W occurs in ≈1.4% of all
rifampicin-resistant isolates, respectively (7). Mutations
outside the RRDR account for <4% of rifampicin resist-
ance, and few have been described (7–9). In a previous
study (7), V176F was found in 5 of 18 isolates with no
mutations in the RRDR from Asia (9,10) and Africa
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mutation has been detected in strains isolated in the United
Kingdom.
Three different mutations in the rpoB gene, V176F,
H526R and S531W, were detected in the isolates associat-
ed with the isoniazid-resistant outbreak. Given that all the
mutations found in this study are rare and that MDR-TB
developed during treatment in 3 patients (018, 483, and
915) (Figure 2), the rifampicin-resistance mutations
observed in these 3 patients likely occurred on 3 independ-
ent occasions, as a result of poor compliance with therapy.
Two of these patients, 018 and 915, were contacts of the 3
patients who subsequently had primary MDR-TB (patients
T7 and 604 [V176F] and 317 [S531W]) (Figure 2).
Conclusions
Our study highlights problems associated with using a
line probe hybridization assay to detect rifampicin resist-
ance in M. tuberculosis. The Inno-LiPA assay cannot
detect mutations outside the RRDR, and failure to detect
rare mutations within the RRDR may be caused by non-
specific hybridization of the wildtype S-probes because of
slight fluctuations in temperature during the hybridization
process. In this study, all the rare mutations, inside and out-
side the RRDR, were detected by sequencing the entire
rpoB gene. The inability to identify MDR-TB isolates
results in treatment failure and increased risk for transmis-
sion of resistant disease in the community. We recommend
that, when the index of suspicion for MDR-TB is high and
the line probe assays fail to detect mutations conferring
rifampicin resistance, the entire rpoB gene should be
sequenced to prevent unnecessary delay in diagnosing
MDR-TB.
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